Table 2.
Outcomes across COVID-19 stringency index groups for patients going straight to surgery (no neoadjuvant therapy)
| Light restrictions (n=4152) | Moderate lockdown (n=3057) | Full lockdown (n=8402) | Total*(N=15 622) | p value† | |
|---|---|---|---|---|---|
| Margin status | |||||
| R0 | 3471 (83·7%) | 2619 (85·8%) | 7238 (86·3%) | 13 328 (85·5%) | 0·0011 |
| R1 | 381 (9·3%) | 223 (7·4%) | 581 (6·9%) | 1185 (7·7%) | .. |
| R2 | 79 (1·9%) | 61 (2·0%) | 157 (1·9%) | 297 (1·9%) | .. |
| Pathology unavailable | 214 (5·2%) | 147 (4·8%) | 407 (4·8%) | 768 (4·9%) | .. |
| Missing | 7 | 7 | 19 | 33 | .. |
| Resectable disease at time of surgery | |||||
| Resectable | 4069 (98·0%) | 2967 (97·1%) | 8213 (97·8%) | 15 249 (97·7%) | 0·045 |
| Unresectable | 81 (2·0%) | 90 (2·9%) | 187 (2·2%) | 358 (2·3%) | .. |
| Unknown | 2 | 0 | 2 | 4 | .. |
| Pre-operative cancer-related complication requiring emergency surgery‡ | |||||
| Elective | 4071 (98·2%) | 2989 (97·8%) | 8199 (97·8%) | 15 259 (97·9%) | 0·27 |
| Emergency | 74 (1·8%) | 67 (2·2%) | 185 (2·2%) | 326 (2·1%) | .. |
| 30-day SARS-CoV-2 infection rate‡ | |||||
| No | 4083 (98·3%) | 3039 (99·4%) | 8362 (99·5%) | 15 484 (99·2%) | <0·0001 |
| Yes | 69 (1·7%) | 18 (0·6%) | 40 (0·5%) | 127 (0·8%) | .. |
| 30-day postoperative mortality rate‡ | |||||
| No | 4080 (98·3%) | 3016 (98·7%) | 8307 (99·0%) | 15 403 (98·8%) | 0·0045 |
| Yes | 70 (1·7%) | 41 (1·3%) | 84 (1·0%) | 195 (1·2%) | .. |
| Missing | 2 | 0 | 11 | 13 | .. |
| New detection of metastatic disease§ | |||||
| No | 2191 (98·3%) | 1625 (98·3%) | 4946 (98·2%) | 8762 (98·2%) | 0·87 |
| Yes | 38 (1·7%) | 28 (1·7%) | 93 (1·8%) | 159 (1·8%) | .. |
| Missing | 7 | 5 | 15 | 27 | .. |
Data are n (%) or n. Patients with metastatic disease at baseline removed from denominator (N=8957). Percentages presented by column total; missing data are excluded. R0=no microscopic or macroscopic disease. R1=microscopic disease at the margin. R2=macroscopic disease at the margin.
*
11 missing this data point.
†
χ2 comparing light versus moderate versus full lockdowns for each outcome.
‡
Subgroups defined in the appendix (p 62).
§
Detailed data on detection of new metastatic disease not collected for liver, pancreatic, breast, and gynaecological cancers.